oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome
Department of Gynecological Oncology, Örebro University Hospital, Örebro, Sweden.
Department of Gynecological Oncology, Örebro University Hospital, Örebro, Sweden.ORCID iD: 0000-0002-5063-631X
Department of Pathology, Örebro University Hospital, Örebro, Sweden.ORCID iD: 0000-0001-6881-237X
2002 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 12, no 3, p. 290-298Article in journal (Refereed) Published
Abstract [en]

The objective of this study was to assess the value of p53, bcl-2, and p21(WAF1/CIP1) immunoreactivity as predictors of pelvic lymph node metastases (LNM), recurrences, and death due to the disease in early stage (FIGO I-II) cervical carcinomas. FIGO stage, type of histopathology, and tumor grade were also evaluated in this series of patients treated by radical hysterectomy (Wertheim-Meigs) between 1965 and 1990. A total of 172 patients were included. A tumor was regarded as positive when more than 30% of the neoplastic cells exhibited immunoreactivity. Positive immunostaining was found in 8.9% for p53, in 43.5% for bcl-2, and in 25.0% for p21(WAF1/CIP1). None of them was able to predict LNM or clinical outcome. Presence of LNM, tumor recurrence, and death from disease were significantly associated with the FIGO stage (P = 0.014, P = 0.009, and P = 0.001, respectively). The 5-year cancer-specific survival rate was 91.6% and the overall survival rate was 90.5%. It was concluded that immunohistochemically detected p53, bcl-2, and p21(WAF1/CIP1) appeared to be of no predictive value with regard to LNM, tumor recurrences, or long-term survival in early cervical carcinomas.

Place, publisher, year, edition, pages
Malden, USA: Blackwell Publishing, 2002. Vol. 12, no 3, p. 290-298
National Category
Cancer and Oncology Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:oru:diva-49510DOI: 10.1046/j.1525-1438.2002.01113.xISI: 000176131400009PubMedID: 12060451Scopus ID: 2-s2.0-0036071265OAI: oai:DiVA.org:oru-49510DiVA, id: diva2:914903
Available from: 2016-03-27 Created: 2016-03-25 Last updated: 2018-02-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Sorbe, BengtKarlsson, Mats G

Search in DiVA

By author/editor
Sorbe, BengtKarlsson, Mats G
In the same journal
International Journal of Gynecological Cancer
Cancer and OncologyClinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 293 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf